BioValues

Biotech investor. Tend to focus on contrarian names, so I'm probably buying what you are selling/hating on. All tweets are my opinions only.

[BioValues @BioValues]

$CRBP now up to 1000 Dec $22.50 calls bought. Seems like someone accumulating at $1

[BioValues @BioValues]

$CRBP bidder keeps flashing the $1. Now up to 734 calls

[BioValues @BioValues]

$CRBP 600 Dec $22.50 calls bought around $1

[Clinaptis Research @Clinaptis]

$CRBP — CANYON-1 P1b obesity readout, Sept.

The tape is pricing another failed-CB1 shot. We read it differently: a therapeutic-index test on a mechanism already validated in humans.

Rimonabant drove ~4.7kg placebo-adj weight loss (WL) 20 years ago, before psychiatric toxicity buried the class in 2008. Efficacy was real. The index was what failed.

So the real test for CRB-913, its oral peripheral CB1 inverse agonist: does the effect survive once CB1 blockade is pushed out of the brain — without recreating rimonabant's CNS toxicity?

[BioValues @BioValues]

@Random132Person I sold since they lost their Nasdaq listing to use for a merger

[BioValues @BioValues]

Current positions for rest of year in order of size: $NKTX (data Nov, below cash), $CRBP (data Sept), $PEPG (data Nov), $BOLT (data Nov), $BCAB (lotto for strategic alternatives). Sold $ACET due to data delay and CMO leaving

[BioValues @BioValues]

@CameronQuilter2 Thanks. Just stock

[BioValues @BioValues]

$XBI Updated account performance since the biotech bottom in April 2025 (17 months ago). Balance was sitting around $100k at that time frame. Continue to solely focus on the contrarian names (ones left for dead, under cash, have many skeptics etc), despite having a catalyst)

[BioValues @BioValues]

@RichardTip17589 Thanks

[BioValues @BioValues]

I know $XBI can't always go up but what news is hitting biotech today?

[BioValues @BioValues]

$CRBP maybe some tea leaves? Company posted this the other day, which is about 2-3 weeks away from data. CEO and CFO both reposted it on Linkedin. And several employees and the Chair of the Board liked the post.

[BioValues @BioValues]

@thecellengineer May be even more potent given they are engineered NK and CD19

[BioValues @BioValues]

@Jonny_fun_guy Thanks

[BioValues @BioValues]

@academianlcap @AaronRosenblum5 @Jul05310473John why would that be concerning? If anything I take it as a positive they are still touting with data weeks away (multiple CRBP employees liked the same Linkedin Post, including the Chair of the Board)

[BioValues @BioValues]

@monaco_biotech thanks man

[BioValues @BioValues]

@NJ_Capital_ thanks

[Corbus Pharma @CorbusPharma]

Early research suggests CRB-913 may amplify the effectiveness of popular diabetes and #obesity treatments like tirzepatide & semaglutide, potentially supporting sustained weight loss without excess muscle loss or neuropsychiatric effects. Learn more: https://t.co/LARNJQJoWB

[BioValues @BioValues]

@Mahmissa thanks mah!

[BioValues @BioValues]

$PEPG looks like runup traders/penny flippers exiting today. No reason to exit now with data in Nov lol

[BioValues @BioValues]

$CRBP hefty volume again today. Someone continues to accumulate in size ahead of obesity data

[BioValues @BioValues]

@AaronRosenblum5 Gotta wonder who is betting on obesity via ATM

[BioValues @BioValues]

$CRBP some serious tute buying today eating up ATM